Literature DB >> 21595845

Nuclear chromatin-concentrated osteoblasts in renal bone diseases.

Junichiro James Kazama1, Suguru Yamamoto, Ichiei Narita, Satoshi Kurihara.   

Abstract

The morphological appearance of an osteoblast largely alters with its differentiation and maturation, along with the change of cell function. We quantitatively observed the osteoblast morphology and compared it with bone metabolism. Biopsied iliac bone samples obtained from 77 dialysis patients (14 mild change, 37 osteitis fibrosa, 2 osteomalacia, 8 mixed, and 16 adynamic bone) were included in the study. Osteoblast appearances were classified into three groups: (i) type II and III osteoblasts, namely, active osteoblasts characterized by cuboidal or columnar shapes with or without a nuclear clear zone; (ii) type IV osteoblasts, lining osteoblasts characterized by extremely thin cytoplasm; and (iii) type V osteoblasts, apoptotic osteoblasts characterized by nuclear chromatin concentration. The results were quantitatively expressed as the length of bone surface covered by each type of osteoblasts. The type II and III osteoblasts were predominant in osteitis fibrosa, mixed, and mild change. The type IV osteoblasts were overwhelmingly predominant in adynamic bone. The type V osteoblasts appeared most frequently in osteitis fibrosa, followed by mixed and mild change. Both absolute and relative lengths of bone surface covered by the type V osteoblasts were significantly higher in the high-turnover bone group (osteitis fibrosa and mixed) than the low-turnover bone group (adynamic bone and osteomalacia). The type V osteoblasts were slightly correlated with serum intact parathyroid hormone levels. In conclusion, a high bone-turnover condition seems to be associated with the promotion of osteoblastic apoptosis in dialysis patients. This finding may explain the fact that osteopenia develops faster in CKD patients with high turnover of bone.
© 2011 The Authors. Therapeutic Apheresis and Dialysis © 2011 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595845     DOI: 10.1111/j.1744-9987.2011.00919.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  3 in total

1.  Chronic kidney disease and bone metabolism.

Authors:  Junichiro James Kazama; Koji Matsuo; Yoshiko Iwasaki; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2015-02-05       Impact factor: 2.626

Review 2.  Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.

Authors:  Yoshiko Iwasaki; Junichiro James Kazama; Masafumi Fukagawa
Journal:  Biomed Res Int       Date:  2017-03-22       Impact factor: 3.411

Review 3.  Chronic kidney disease and fragility fracture.

Authors:  Junichiro James Kazama
Journal:  Clin Exp Nephrol       Date:  2016-12-23       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.